PapersFlow Research Brief
Oral health in cancer treatment
Research Guide
What is Oral health in cancer treatment?
Oral health in cancer treatment refers to the pathobiology, incidence, severity, management, and prevention of oral complications such as mucositis and osteoradionecrosis in patients undergoing cancer therapies including radiotherapy and chemotherapy.
This field encompasses 27,180 works addressing mucositis as a common side-effect of anticancer therapies. Sonis (2004) in 'The pathobiology of mucositis' details the biological mechanisms underlying mucosal injury. Trotti et al. (2003) in 'Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review' report high incidence rates in head and neck cancer patients.
Topic Hierarchy
Research Sub-Topics
Pathobiology of Oral Mucositis
This sub-topic elucidates cellular and molecular mechanisms of mucosal injury from cancer therapies. Researchers study inflammatory cascades, apoptosis, and microbiome roles in mucositis development.
Radiotherapy-Induced Osteoradionecrosis
This sub-topic investigates bone necrosis pathophysiology following head and neck radiation. Researchers explore hyperbaric oxygen and preventive protocols for mandibular complications.
Management Guidelines for Mucositis
This sub-topic develops evidence-based protocols like MASCC/ISOO for mucositis treatment. Researchers assess cryotherapy, palifermin, and oral care efficacy in clinical trials.
Chemotherapy-Associated Oral Complications
This sub-topic examines stomatitis, xerostomia, and infections in chemo patients. Researchers quantify incidence and correlate with regimen intensity via meta-analyses.
Quality of Life in Mucositis Patients
This sub-topic evaluates pain, nutrition, and psychosocial impacts using validated instruments. Researchers link mucositis severity to patient-reported outcomes in head and neck cancer.
Why It Matters
Oral health complications like mucositis affect quality of life and treatment outcomes in cancer patients. Sonis et al. (2004) in 'Perspectives on cancer therapy-induced mucosal injury' emphasize that understanding mucositis pathobiology is essential for research progress, with incidence and scoring critical for care. Elad et al. (2020) in 'MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy' provide updated guidelines based on systematic review, addressing systemic sequelae such as impacts on radiotherapy and chemotherapy completion. Trotti et al. (2003) systematic review documents mucositis severity in head and neck cancer patients receiving radiotherapy with or without chemotherapy, linking it to associated outcomes like pain and treatment interruptions.
Reading Guide
Where to Start
'The pathobiology of mucositis' by Sonis (2004) provides foundational understanding of mucosal injury mechanisms essential before exploring clinical applications.
Key Papers Explained
Sonis (2004) in 'The pathobiology of mucositis' establishes core mechanisms, which Sonis et al. (2004) in 'Perspectives on cancer therapy-induced mucosal injury' expands to incidence and scoring perspectives. Trotti et al. (2003) in 'Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review' builds on these by quantifying rates in specific treatments, while Elad et al. (2020) in 'MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy' synthesizes evidence into actionable guidelines. Marx (1983) in 'Osteoradionecrosis: A new concept of its pathophysiology' complements with radiation-specific pathophysiology.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent guidelines by Elad et al. (2020) in 'MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy' represent the current standard, focusing on systematic updates for mucositis management amid stable publication growth.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Meta-analysis of chemotherapy in head and neck cancer (MACH-NC... | 2009 | Radiotherapy and Oncology | 3.0K | ✕ |
| 2 | Mesenchymal stem cells for treatment of steroid-resistant, sev... | 2008 | The Lancet | 2.7K | ✕ |
| 3 | Prevalence of pain in patients with cancer: a systematic revie... | 2007 | Annals of Oncology | 1.9K | ✓ |
| 4 | Development of the Wisconsin Brief Pain Questionnaire to asses... | 1983 | Pain | 1.6K | ✕ |
| 5 | Perspectives on cancer therapy-induced mucosal injury | 2004 | Cancer | 1.4K | ✓ |
| 6 | The pathobiology of mucositis | 2004 | Nature reviews. Cancer | 1.3K | ✕ |
| 7 | Osteoradionecrosis: A new concept of its pathophysiology | 1983 | Journal of Oral and Ma... | 1.3K | ✕ |
| 8 | Mucositis incidence, severity and associated outcomes in patie... | 2003 | Radiotherapy and Oncology | 1.2K | ✕ |
| 9 | MASCC/ISOO clinical practice guidelines for the management of ... | 2020 | Cancer | 1.2K | ✓ |
| 10 | Rapid Hematopoietic Recovery After Coinfusion of Autologous-Bl... | 2000 | Journal of Clinical On... | 1.1K | ✕ |
Frequently Asked Questions
What is the pathobiology of mucositis?
Mucositis arises from complex biological processes triggered by cancer therapies. Sonis (2004) in 'The pathobiology of mucositis' outlines its mechanisms. Understanding these processes supports development of incidence scoring and management strategies.
What are clinical practice guidelines for mucositis management?
MASCC/ISOO guidelines recommend evidence-based interventions for mucositis secondary to cancer therapy. Elad et al. (2020) in 'MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy' update these through systematic review. The guidelines target prevention and treatment of this significant toxicity.
What is the incidence of mucositis in head and neck cancer radiotherapy?
Mucositis occurs frequently in head and neck cancer patients treated with radiotherapy. Trotti et al. (2003) in 'Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review' quantify its incidence and severity. Associated outcomes include impacts on patient quality of life.
What causes osteoradionecrosis?
Osteoradionecrosis results from radiation-induced tissue damage in the jaw. Marx (1983) in 'Osteoradionecrosis: A new concept of its pathophysiology' proposes a new pathophysiological model. This condition complicates oral health in head and neck radiotherapy patients.
How does mucositis impact cancer therapy?
Mucositis leads to pain, treatment delays, and reduced quality of life. Sonis et al. (2004) in 'Perspectives on cancer therapy-induced mucosal injury' highlight its role as a common side-effect. Accurate scoring aids in managing these effects during chemotherapy and radiotherapy.
Open Research Questions
- ? How can pathobiological insights from mucositis models improve prevention in radiotherapy patients?
- ? What factors determine osteoradionecrosis severity beyond radiation dose?
- ? Which interventions most effectively reduce mucositis incidence in head and neck cancer chemotherapy?
- ? How do mucositis outcomes correlate with long-term quality of life in cancer survivors?
- ? What gaps exist in current MASCC/ISOO guidelines for managing therapy-induced oral complications?
Recent Trends
The field maintains 27,180 works with no specified 5-year growth rate.
Elad et al. in 'MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy' marks a key update to guidelines, reflecting ongoing refinement in mucositis management practices.
2020Research Oral health in cancer treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Oral health in cancer treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers